Cambridge Healthtech’s Inaugural

Point-of-Care Product Strategies

Understanding Point-of-Care Testing Markets to Launch Successful Products

August 20, 2019


The in vitro diagnostics market is highly segmented and rapidly growing. In 2022, the global market is expected to grow to tens of billions of dollars, with one of the largest drivers being the growing point-of-care market. In this rapidly changing market place, how can test developers compete and break into competitive markets? How has the testing landscape changed, and what are the opportunities? At Cambridge Healthtech Institute's Inaugural Point-of-Care Product Strategies attendees will understand and learn how to better overcome challenges that they are facing in bringing point-of-care products to market.

Final Agenda

Tuesday, August 20, 2019

1:00 pm Registration

1:30 Chairperson’s Opening Remarks

Lawrence J. Worden, Founder, Principal, IVD Logix

1:35 OPENING KEYNOTE PRESENTATION: How Disruptive Could Disruptive Technology Be?

Tsongalis_GregoryGregory J. Tsongalis, PhD, HCLD, CC, Professor, Pathology, Director, Laboratory for Clinical Genomics and Advanced Technology (CGAT), Pathology and Laboratory Medicine, Dartmouth Hitchcock Health System, The Audrey and Theodor Geisel School of Medicine at Dartmouth

The world of diagnostic laboratory medicine has and continues to evolve at a rapid pace. Numerous drivers are responsible for this change but none more so than the so-called disruptive technologies. Here we discuss this trend.


2:00 Point-of-Care: Overview of Global Market Size, Growth, and Future Outlook


Mark Hughes, MBA, Vice President, Enterprise Analysis Corporation

2:15 Trends and Countertrends in Point-of-Care Diagnostics

hattingh_LucyLucy Hattingh, MBA, Principal, Lucy Hattingh Consulting

2:30 POCT Future in China- Reasons for Optimism and Cautions

Whitney_NathanielNathaniel Whitney, President, Whitney Research

2:45 Panel Discussion with Session Speakers

  • Opportunities and strategies for implementation across different markets including hospital, clinic, resource-limited setting, pharmacy, home
  • Determining the how, when, and why of point-of-care in the market
  • Global market size, growth, and trend analysis
  • Understanding emerging and reemerging markets

3:00 Battle Studies: How Successful Companies Commercialize Innovative Rapid Diagnostic Technologies

schmidt_ryanRyan Schmidt, Vice President of Sales & Marketing, Click Diagnostics

There is a tremendous need and opportunity to democratize diagnostic technologies so that they can empower more personalized care in a more efficient manner. During this session we will discuss case studies that will illuminate what happens when you “cut the cord” and how to navigate the competitive pressures to drive adoption.

3:35 Refreshment Break in the Exhibit Hall with Poster Viewing

4:25 PANEL DISCUSSION: Current Status – Future Promise, Clinical Perspectives on POC Implementation

Worden_LawrenceModerator: Lawrence J. Worden, Founder, Principal, IVD Logix

Mumford_JeannePanelists: Jeanne Mumford, MT(ASCP), Pathology Manager I, Point of Care Testing, Johns Hopkins Medicine; President, KEYPOCC

campos_josephJoseph Campos, PhD, D(ABMM), F(AAM), Director, Microbiology Laboratory, Infectious Disease Molecular Diagnostics Laboratory, Laboratory Informatics, Children’s National Medical Center

Christenson_RobRobert H. Christenson, PhD, Professor, Pathology; Professor Medical and Research Technology, University of Maryland School of Medicine

  • Where have you been able to successfully implement point-of-care in your institution?
  • Where have there been failures?
  • What are the challenges and opportunities presented by new point-of-care diagnostics?
  • Lessons learned and best practices
  • What are you looking for in a POC diagnostic?
  • Future perspectives, what are some of the unmet needs and emerging technologies?

5:10 PANEL DISCUSSION: Reimbursement and Pricing Considerations

Jones_MarcModerator: Marc R. Jones, Chief Operating Officer & CFO, Binx Health

pratt_victoriaPanelists: Victoria Pratt, PhD, FACMG, Director, Pharmacogenomics and Molecular Genetics Laboratories, Medical and Molecular Genetics, Indiana University School of Medicine; President, Association of Molecular Pathology

Girardi_Mark_IDXMark Girardi, Vice President, Boston Healthcare Associates

  • Reimbursement models in point-of-care testing
  • Balancing value and price in test development
  • Working with reimbursement and regulatory agencies
  • Reimbursement planning throughout the product development process.

6:00 End of Point-of-Care Product Strategies

6:00 Wine & Cheese Pairing Welcome Reception in the Exhibit Hall with Poster Viewing

7:00 Close of Day

Recommended Short Course*

SC14: Generating Evidence and Creating a Winning Dossier for Regulatory and Reimbursement Needs

Mark Hiatt, MD, Vice President, Guardant Health

John Sninsky, PhD, Consultant, Translational Sciences

Managing the clinical narrative for your diagnostic test requires careful evaluation of the evidentiary requirements of stakeholders. Using those evidentiary requirements to determine your clinical and economic study designs is the cornerstone of effective product development.

*Separate registration required click here for details.